Radar Telegram alerts Open Radar

The US Food and Drug Administration (FDA) has approved GSK's British drug Nelcarmi for the treatment of non-small cell lung cancer, reports the Financial Times. The drug became a central asset in the purchase of the American biotechnology company Nuvalent for $10.6 billion in June. According to Jefferies analysts, peak sales for the purchased pipeline could range from $5 billion to $7 billion.

תרגם לעברית

Кролик с Неглинной · · Source

🇺🇸 USA · Map

The US Food and Drug Administration (FDA) has approved GSK's British drug Nelcarmi for the treatment of non-small cell lung cancer, reports the Financial Times. The drug became a central asset in the purchase of the American biotechnology company Nuvalent for $10.6 billion in June. According to Jefferies analysts, peak sales for the purchased pipeline could range from $5 billion to $7 billion.

More on Radar

Want to see every report in real time?

Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.

Sign up free
Share on WhatsApp Get alerts on Telegram